Adherex Technologies Inc. (FENC) closed the last trading session at $6.19, gaining 11.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $13.20 indicates an 113.3% upside potential.The mean estimate comprises five short-term price targets with a standard deviation of $2.05. While the lowest estimate of $10 indicates a 61.6% increase from the current price level, the most optimistic ...

A downtrend has been apparent in Adherex Technologies Inc. (FENC) lately with too much selling pressure. The stock has declined 22.2% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.Here is How to Spot Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indic ...

Financial Performance - As of December 31, 2024, the company had $24.6 million in money market investments, an increase from $11.9 million at December 31, 2023, indicating a significant growth in liquid assets [555]. - The company has not experienced any loss or write-down of its money market investments for the years ended December 31, 2024, and 2023, reflecting stable investment performance [556]. - The company has a history of significant losses and limited revenue generation from product sales since inception, highlighting financial challenges [15]. Investment Strategy - The investment policy prioritizes preservation of principal, liquidity, and return on investment, with minimal risk associated with fluctuating interest rates [557]. Regulatory and Market Challenges - The commercialization of PEDMARK® is critical, as the company is a single product entity with limited commercial experience, complicating future financial forecasts [19]. - Regulatory approvals for PEDMARK® have been obtained, but ongoing regulatory review and potential restrictions remain a concern for market acceptance [19]. - The company may require additional financing for further product development and regulatory approvals, which could impact operational capabilities [15]. - The company faces substantial competition in the biopharmaceutical market, which could adversely affect its market position and financial performance [19]. Operational Risks - The company is subject to foreign currency risks, holding approximately CAD$0.16 million and €0.24 million as of December 31, 2024, to manage obligations in Canada and the EU [558]. - The company relies on third parties for raw materials and manufacturing, and any failure in their performance could materially impact business operations [17].

Financial Performance - Full-Year PEDMARK® net product sales reached $29.6 million, a 40% increase year-over-year, with Q4 2024 net product sales of $7.9 million[1] - The company reported a Q4 2024 EBITDA loss of $0.6 million and had $26.6 million in cash, cash equivalents, and short-term investments[1] - Cash flow from operations decreased by $0.6 million in Q4 2024, but there was a $13.4 million increase in cash and cash equivalents from December 31, 2023, to December 31, 2024[7] - Selling and marketing expenses for FY 2024 were $18.4 million, up from $12.1 million in FY 2023, primarily due to increased payroll and marketing efforts[7] - General and administrative expenses for FY 2024 were $23.1 million, compared to $20.6 million in FY 2023, influenced by European pre-commercialization expenses and costs associated with the Norgine transaction[8] Debt Management - Early repayment of $13 million of the company's convertible debt facility was completed, optimizing the balance sheet and saving approximately $1.5 million in future annual interest payments[7] Product Development and Approval - PEDMARK® is the first FDA-approved therapy to reduce the risk of ototoxicity associated with cisplatin in pediatric patients with localized, non-metastatic solid tumors[18] - PEDMARK received FDA approval in September 2022, European Commission approval in June 2023, and U.K. approval in October 2023[31] - The Japan clinical trial (STS-J01) for PEDMARK® is fully enrolled, with results expected in the second half of 2025, potentially leading to registration in Japan[7] - PEDMARQSI® is now commercially available in the United Kingdom and Germany, expanding global access to the product[2] Clinical Efficacy and Safety - PEDMARK has proven efficacy and safety data established through two Phase 3 clinical studies, COG ACCL0431 and SIOPEL 6[21] - The COG ACCL0431 protocol enrolled patients with various childhood cancers treated with intensive cisplatin therapy, while SIOPEL 6 focused on hepatoblastoma patients[21] - Hypersensitivity reactions occurred in 8% to 13% of patients during clinical trials, necessitating monitoring for such reactions[25] - Hypernatremia occurred in 12% to 26% of patients, while hypokalemia occurred in 15% to 27% of patients during clinical trials[27] - The most common adverse reactions in SIOPEL 6 were vomiting, nausea, decreased hemoglobin, and hypernatremia, while hypokalemia was most common in COG ACCL0431[29] Market Potential and Strategy - Over 10,000 children in the U.S. and Europe may receive platinum-based chemotherapy annually, with many requiring lifelong hearing aids due to ototoxicity[20] - Fennec Pharmaceuticals emphasizes the potential market impact and commercialization plans for PEDMARK, alongside anticipated regulatory milestones and funding opportunities[32] - The company is focused on expanding access to PEDMARQSI® for cancer patients at risk of hearing loss, with significant milestones achieved in Europe[5]

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q4 2024 Earnings Conference Call March 10, 2025 8:30 AM ET Company Participants Robert Andrade - CFO Jeff Hackman - CEO and Board Member Conference Call Participants Chase Knickerbocker - Craig-Hallum Raghuram Selvaraju - H.C. Wainwright Felix Ampomah - Stephens Michael Okunewitch - Maxim Group Operator Good morning, ladies and gentlemen, and welcome to Fennec Pharmaceuticals Fourth Quarter and Full Year 2024 Earnings and Corporate Update Conference Call. At this ti ...

Financial Data and Key Metrics Changes - In 2024, the company reported a revenue growth of approximately 40% year-over-year, with net product sales of $29.6 million compared to $21.3 million in 2023 [28][30] - For Q4 2024, net product sales were $7.9 million, reflecting a quarterly growth rate of approximately 13% [28] - The company managed to burn only approximately $0.6 million in cash for Q4 2024, demonstrating operational efficiency [34] Business Line Data and Key Metrics Changes - The pediatric segment continued to show growth, while the adolescent and young adult (AYA) segment emerged as a significant opportunity [38] - Selling and marketing expenses for Q4 2024 were $3.9 million, down from $4.6 million in Q3 2024, while full-year expenses increased to $18.4 million from $12.1 million in the previous year [29][30] Market Data and Key Metrics Changes - The U.S. AYA oncology landscape is estimated to have approximately 20,000 cisplatin chemotherapy patients treated annually, with significant market potential [11] - The product PEDMARK is gaining traction in major academic centers, which is critical for broader market acceptance [14] Company Strategy and Development Direction - The company is focused on expanding awareness of the unmet need for preventing cisplatin-induced ototoxicity and establishing PEDMARK as the standard of care [9][10] - The PEDMARK strategy will be utilized throughout 2025 to drive growth, with a focus on increasing adoption among oncologists and ensuring access for patients [7][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential for PEDMARK, particularly in the AYA segment, and anticipates significant growth in the second half of 2025 [41][42] - The company is actively engaging with stakeholders to support the inclusion of PEDMARK in key compendia, which is expected to enhance access and reimbursement pathways [17][18] Other Important Information - The company has launched PEDMARQSI in Germany and the U.K., with pricing set at £8277 in the U.K. and over €10,500 in Germany [20][21] - The company anticipates receiving a €10 million milestone upon obtaining final pricing approval in Germany [34] Q&A Session Summary Question: Did the pediatric business return to sequential growth in Q4, and what was the AYA contribution? - Management confirmed continued growth in the pediatric segment and highlighted the AYA segment as an incredible opportunity, though specific breakdowns were not provided [38] Question: What is the expected inflection in the AYA segment for 2025? - Management indicated significant opportunities in the AYA segment and expects accelerated growth in the second half of the year [41][42] Question: What progress has Norgine made in Europe regarding key centers of excellence? - Management noted that the product is now commercially available in the U.K. and Germany, with ongoing updates expected as more countries are approved [48][49] Question: What is the competitive landscape for PEDMARK in the U.S.? - Management acknowledged the presence of compounded products but emphasized the adoption of PEDMARK in major institutions, indicating progress despite competition [72] Question: Will clinical trials be run for potential label expansions? - Management indicated openness to discussions regarding label expansions and will provide updates as developments occur [75]

Core Viewpoint - Adherex Technologies Inc. reported a quarterly loss of $0.06 per share, significantly missing the Zacks Consensus Estimate of $0.56, marking an earnings surprise of -110.71% [1][2] Financial Performance - The company posted revenues of $7.93 million for the quarter ended December 2024, which was 73.17% below the Zacks Consensus Estimate and down from $9.74 million year-over-year [2] - Over the last four quarters, Adherex Technologies has not surpassed consensus EPS estimates and has only topped revenue estimates once [2] Stock Performance - Adherex Technologies shares have increased by approximately 8.9% since the beginning of the year, contrasting with a -1.9% decline in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.17 on revenues of $8.7 million, and for the current fiscal year, it is -$0.15 on revenues of $57.11 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Adherex Technologies belongs, is currently ranked in the top 26% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Core Viewpoint - Fennec Pharmaceuticals Inc. is set to release its full year and fourth quarter 2024 financial results on March 10, 2025, and will host a conference call to discuss these results [1][2]. Company Overview - Fennec Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing PEDMARK®, which aims to reduce the risk of platinum-induced ototoxicity in pediatric patients [3]. - PEDMARK received FDA approval in September 2022, European Commission approval in June 2023, and U.K. approval in October 2023 under the brand name PEDMARQSI [3]. - The product has been granted Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, providing eight years plus two years of data and market protection [3]. Conference Call & Webcast Details - The conference call is scheduled for March 10, 2025, at 8:30 a.m. Eastern Time, with a live webcast available [2]. - Participants are advised to connect to the company's website at least 15 minutes prior to the call for any necessary software downloads [2]. - A replay of the conference call will be archived on the company's website for thirty days [2].

Group 1 - The stock of Adherex Technologies (FENC) is experiencing significant attention due to high implied volatility in the options market, particularly the Feb 21, 2025 $05.00 Call option [1] - Implied volatility indicates the market's expectation of future price movement, suggesting that investors anticipate a significant change in the stock's price, potentially due to an upcoming event [2] - Adherex Technologies holds a Zacks Rank 3 (Hold) in the Medical-Biomedical and Genetics industry, which is in the top 30% of the Zacks Industry Rank, indicating a relatively stable outlook [3] Group 2 - Over the past 60 days, one analyst has raised the earnings estimate for the current quarter while another has lowered it, leading to a shift in the Zacks Consensus Estimate from a loss of 11 cents per share to a gain of 56 cents [3] - The high implied volatility may signal a developing trading opportunity, as options traders often seek to sell premium on options with high implied volatility, aiming to benefit from time decay [4]

Group 1 - Fennec Pharmaceuticals Inc. will participate in the 15th Annual Craig-Hallum Alpha Select Conference on November 19, 2024, at the Sheraton New York Times Square Hotel [1][2] - The company focuses on the development and commercialization of PEDMARK, aimed at reducing the risk of platinum-induced ototoxicity in pediatric patients [2] - PEDMARK received FDA approval in September 2022, European Commission approval in June 2023, and U.K. approval in October 2023 under the brand name PEDMARQSI [2] Group 2 - PEDMARK has Orphan Drug Exclusivity in the U.S., while PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, providing eight years plus two years of data and market protection [2]